CRISPR THERAPEUTICS AG Current Liabilities
CRISPR THERAPEUTICS AG (CRSP) had Current Liabilities of $132.90 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-03
- 2026-06-30: Liabilities, Current $132.90M.
- 2026-03-31: Liabilities, Current $136.29M.
- 2025-12-31: Liabilities, Current $149.12M.
- 2025-09-30: Liabilities, Current $118.96M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $132.90M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $136.29M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $149.12M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $118.96M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $104.36M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $119.45M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $87.78M 10-K · filed 2026-02-12 |
| 2024-09-30 | $89.81M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $127.82M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $118.99M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $108.79M 10-K · filed 2025-02-11 |
| 2023-09-30 | $111.23M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $132.84M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $146.79M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $121.11M 10-K · filed 2024-02-21 |
| 2022-09-30 | $150.87M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $119.96M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $113.70M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $119.88M 10-K · filed 2023-02-21 |
| 2021-09-30 | $96.21M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $99.92M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $83.09M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $94.26M 10-K · filed 2022-02-15 |
| 2020-09-30 | $84.15M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $74.50M 10-Q · filed 2020-07-27 |
| 2020-03-31 | $55.09M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $57.11M 10-K · filed 2021-02-16 |
| 2019-09-30 | $79.78M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $31.41M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $28.40M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $27.75M 10-K · filed 2020-02-12 |
| 2018-09-30 | $32.28M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $18.48M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $14.39M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $14.51M 10-K · filed 2019-02-25 |
| 2017-09-30 | $12.12M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $15.81M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $16.91M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $22.00M 10-K · filed 2018-03-08 |
| 2016-09-30 | $78.10M 10-Q · filed 2016-11-22 |
| 2015-12-31 | $10.15M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |